de La Torre REE, García NLA, Grin PL

Language: Spanish
References: 6
Page: 521-525
PDF size: 279.11 Kb.

Text Extraction

No abstract.

REFERENCES

1. Cruz Rivas EM, Vargas Herrera R, Vera Basterrechea LC, Estévez de la Torre E, Villalón García G. Neuritis óptica como forma de presentación de la esclerosis múltiple. CCM. 2013 [citado 30 mar 2015]; 17(1): 92-7. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S1560-43812013000100016&lng=es

2. Aldinucci A, Biagioli T, Manuelli C, Repice AM, Massacesi L, Ballerini C, et al. Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: a novel mechanism of AZA/6-MP. J Neuroimmunol. 2010 [citado 30 mar 2015]; 218(1):28-35. Disponible en: https://www.clinicalkey.es/#!/search/Modulating%2520dendritic%2520cells%2520%28DC%29%2520from%2520immunogenic%2520to%2520tolerogenic%2520responses%253A%2520a%2520novel%2520mechanism%2520of%2520AZA%252F6-MP

3. Barten LJ, Allington DR, Procacci KA, Rivey MP. New approaches in the management of multiple sclerosis. Drug Des Devel Ther. 2010 [citado 27 mar 2015]; 4: 343-346. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998807/

4. Howell OW, Rundle JL, Garg A, Komada M, Brophy PJ, Reynolds R. Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis. J Neuropathol Exp Neurol. 2010 [citado 30 mar 2015]; 69(10):1017-33. Disponible en: https://www.clinicalkey.es/#!/content/medline/2-s2.0-20838243

5. Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol. 2010 [citado 30 mar 2015]; 9(3):299-308. Disponible en: https://www.clinicalkey.es/#!/search/Combination%2520therapy%2520in%2520multiple%2520sclerosis

6. Johnson KP. Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Therapeutics and clinical risk management. Ther Clin Risk Manag. 2010 [citado 19 mar 2015]; 6: 153–72. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2857614/?tool=pubmed